Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery

Breast Cancer

Volumn 12, Issue 3, 2005, Pages 226-230

  Nomura, Masaya ^a   Inoue, Yoshifumi ^a   Fujita, Shigeo ^a   Sakao, Jun ^a   Hirota, Masaki ^a   Souda, Shigeo ^a   Ohshima, Masato ^a  

^a Nippon Life Saiseikai Foundation   (Japan)

Author keywords

Breast conserving surgery; Inflammatory local recurrence; Paclitaxel; Pathological CR; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CASE REPORT; FEMALE; HUMAN; INFLAMMATION; MASTECTOMY; MIDDLE AGED; PAGET NIPPLE DISEASE; REMISSION; REOPERATION; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INFLAMMATION; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; REMISSION INDUCTION; REOPERATION; TREATMENT OUTCOME;

EID: 27744509502     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.2325/jbcs.12.226     Document Type: Article

References (17)

1. Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL: Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 16:480-486, 1998. (Pubitemid 28135589)
2. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558, 1990. (Pubitemid 20090470)
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
4. Piccart-Gebhart MJ: "Herceptin": the future in adjuvant breast cancer therapy. Anti-Cancer Drugs 12(suppl 4):S27-S33, 2001. (Pubitemid 34164081)
5. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E, Wickerham L, Lerner H, Glass A, Shibata H, Deckers P, Ketcham A, Oishi R, Russell I: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of the breast cancer. N Engl J Med 312:665-673, 1985. (Pubitemid 15134702)
6. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 11:44-48, 1993. (Pubitemid 23059973)
7. Fisher ER, Sass R, Fisher B, Gregorio R, Brown R, Wickerham L, NSABP Investigators: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6). II. Relation of local breast recurrence to multicentricity. Cancer 57:1717-1724, 1986. (Pubitemid 16111978)
8. Kurtz JM, Jacquemier J, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM: Inoperable recurrence after breast-conserving surgical treatment and radiotherapy. Surg Gynecol Obstet 172:357-361, 1991.
9. Nishimura R, Koyama H, Kasumi F, Takashima S, Kobayashi S, Komaki K, Ohkawa T, Shin E, Kodama H, Fukutomi T, Nishi T, Sonoo H, Sano S, Kimishima I, Nakaue K, Nakamura S, Kusama M, Okumura K: A case control study on risk factors involved in inflammatory breast recurrence after breast-conserving surgery. Oncology 55:391-399, 1998. (Pubitemid 28396049)
10. Voogd AC, Peterse JL, Crommelin MA, Rutgers E J T, Botke G, Elkhuizen P H M, Geel AN, Hoekstra C J M, Pel R, Vijver MJ, Coebergh J W W, Dutch Study Group on Local Recurrence after Breast Conservation (BORST): Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Eur J Cancer 35:1828-1837, 1999. (Pubitemid 29514280)
11. Marret H, Perrotin F, Bougnoux P, Giraudeau B, Hubert B, Fetissof F, Le Floch O, Lansac J, Body G: Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers. Breast Cancer Res Treat 68:1-8, 2001. (Pubitemid 32928265)
12. Saltzstein SL: Clinically occult inflammatory carcinoma of the breast. Cancer 34:382-388, 1974.
13. Amparo RS, Angel C D M, Ana LH, Antonio LC, Vicente MS, Carlos FM, Vicente GM: Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat 64:269-273, 2000. (Pubitemid 32055835)
14. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001. (Pubitemid 32441364)
15. R and taxanes. Oncology 61(suppl 2):43-49, 2001.
16. R in primary breast cancer: views from North America and Europe. Oncology 61(suppl 2):83-91, 2001. (Pubitemid 33033429)
17. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(suppl 3):13-19, 2001.